Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 20/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 18/20 | 0.59 |
| ▸ | TSPO | P30536 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777641 | 0.95 | HCRTR1 (0.64) | HCRTR2HCRTR1TSPOOPRK1HTR2B | |
| SCHEMBL6682860 | 0.95 | HCRTR1 (0.64) | HCRTR2HCRTR1TSPOOPRK1HTR2B | |
| SCHEMBL1778402 | 0.93 | HCRTR1 (0.62) | HCRTR2HCRTR1TSPOOPRK1HTR2B | |
| SCHEMBL1778399 | 0.93 | HCRTR1 (0.62) | HCRTR2HCRTR1TSPOOPRK1HTR2B | |
| SCHEMBL1778902 | 0.88 | HCRTR1 (0.64) | HCRTR2HCRTR1TSPOOPRK1HTR2B | |
| SCHEMBL1777725 | 0.86 | HCRTR1 (0.63) | HCRTR2HCRTR1TSPOOPRK1HTR2B | |
| SCHEMBL1776015 | 0.84 | HCRTR1 (0.60) | HCRTR2HCRTR1TSPOOPRK1HTR2B | |
| SCHEMBL1779459 | 0.83 | HCRTR1 (0.58) | HCRTR2HCRTR1TSPOOPRK1HTR2B | |
| SCHEMBL1779440 | 0.83 | HCRTR1 (0.51) | HCRTR2HCRTR1TSPOOPRK1HTR2B | |
| SCHEMBL1257946 | 0.82 | HCRTR1 (0.57) | HCRTR2HCRTR1TSPOOPRK1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | claimed |
| US-7943645-B2 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. | 2009-03-26 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2004-10-28 | — | — | US | disclosed |
| EP-1406897-A2 | COMPOUNDS | SmithKline Beecham plc (GB) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003002559-A2 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HCRTR1 2/4885TSPO 408/4885 |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HCRTR1 2/4885TSPO 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.